"Vector" of Rospotrebnadzor registered the ELISA test system "SARS-CoV-2-ELISA-Vector" to determine antibodies to the new coronavirus, "the report said.

They noted that the development passed all the necessary technical and clinical trials.

According to the agency, the “new diagnostic tool” will allow retrospectively identifying patients who have been ill, studying population immunity and assessing the effectiveness of the developed vaccines against COVID-19.